Indivior Pharmaceuticals, Inc.

INDV · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.8%

Institutions99.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$1.24B	$1.19B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$246.00M	$231.00M
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$994.00M	$957.00M
Gross profit as a percentage of revenue.	80.2%	80.6%
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$262.00M	$32.00M
Operating income as a percentage of revenue.	21.1%	2.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$210.00M	$2.00M
Net income divided by the number of shares outstanding — profit attributable to each share.	$1.68	$0.02
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$1.64	$0.02

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$195.00M	$319.00M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.20B	$1.32B
All of the company's interest-bearing borrowings, short and long term combined.	$319.00M	$333.00M
Everything the company owes — debt, unpaid bills, and other obligations.	$1.30B	$1.67B
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$98.00M	-$348.00M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$27.00M	$36.00M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$66.00M	$29.00M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$93.00M	$7.00M

	You	Peer avg
P/E	12.5	36.3
Revenue Growth	+13.6%	+9.9%
ROE	–	123.9%

Indivior Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison